SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer

Molecular Carcinogenesis

Volumn 53, Issue 10, 2014, Pages 777-786

  Huang, Zhiquan ^a,b,d   Li, Haigang ^b   Huang, Qi ^a,c   Chen, Dan ^b   Han, Jingjing ^b   Wang, Lili ^b   Pan, Chanbin ^b   Chen, Weiliang ^b   House, Michael G ^a   Nephew, Kenneth P ^a,d   Guo, Zhongmin ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresistance; Chemotherapy; Head and neck cancer; Serpin peptidase inhibitor B2(SERPINB2); UPAR signaling

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMORESISTANCE; CHEMOTHERAPY; DOWN REGULATION; DRUG RESISTANCE; FEMALE; GENETICS; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HUMAN; IC 50; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; SERPIN PEPTIDASE INHIBITOR B2(SERPINB2); SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UPAR SIGNALING;

CHEMORESISTANCE; CHEMOTHERAPY; HEAD AND NECK CANCER; SERPIN PEPTIDASE INHIBITOR B2(SERPINB2); UPAR SIGNALING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 2; STAT3 TRANSCRIPTION FACTOR;

EID: 84908346880     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22033     Document Type: Article

References (41)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest 2012;122:1951-1957.
3. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
4. Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 2009;45:409-415.
5. Murdoch D. Standard, and novel cytotoxic and moleculartargeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol 2007;19:216-221.
6. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644-2652.
7. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64:706-721.
8. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle 2008;7:1353-1359.
9. Mandic R, Schamberger CJ, Muller JF, et al. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 2005;11: 6845-6852.
10. Michaud WA, Nichols AC, Mroz EA, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009;15: 1645-1654.
11. Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res 2008;14:5877-5883.
12. Shiga H, Heath EI, Rasmussen AA, et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097-4104.
13. Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z. GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett 2011;309:37-45.
14. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-943.
15. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 2010;584: 1923-1930.
16. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
17. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep 2005;14:105-112.
18. Boonstra MC, Verspaget HW, Ganesh S, et al. Clinical applications of the urokinase receptor (uPAR) for cancer patients. Curr Pharm Des 2011;17:1890-1910.
19. Weng CJ, Tsai CM, Chen YC, et al. Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol 2010;17: 3394-3401.
20. Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-167.
21. Shetty S, Rao GN, Cines DB, Bdeir K. Urokinase induces activation of STAT3 in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;291:L772-L780.
22. Shushakova N, Tkachuk N, Dangers M, et al. Urokinaseinduced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 2005;118:2743-2753.
23. Selvendiran K, Ahmed S, Dayton A, et al. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol Ther 2011;12:837-845.
24. van den Broek GB, Wildeman M, Rasch CR, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 2009;124:2643-2650.
25. Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatinresistance related genes in head and neck squamous cell carcinoma. Int J Cancer 2010;126:437-449.
26. Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 2008;8:535-545.
27. Chen B, Chen J, House MG, Cullen KJ, Nephew KP, Guo Z. Role of neurofilament light polypeptide in head and neck cancer chemoresistance. Mol Cancer Res 2012;10:305-315.
28. Li HG, Han JJ, Huang ZQ, Wang L, Chen WL, Shen XM. IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma. J Craniofac Surg 2011;22: 2022-2025.
29. Mekkawy AH, Morris DL, Pourgholami MH. Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol 2009;5:1487-1499.
30. Shi Z, Stack MS. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 2007;407:153-159.
31. Shiiba M, Nomura H, Shinozuka K, et al. Down-regulated expression of SERPIN genes located on chromosome 18q21 in oral squamous cell carcinomas. Oncol Rep 2010;24:241-249.
32. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 2003; 63:555-559.
33. Park JS, Park JH, Khoi PN, Joo YE, Jung YD. MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. Carcinogenesis 2011;32:175-181.
34. Malla R, Gopinath S, Alapati K, et al. Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas. PLoS ONE 2010;5:e13731.
35. Gutova M, Najbauer J, Gevorgyan A, et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007;2:e243.
36. Leeman-Neill RJ, Wheeler SE, Singh SV, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30:1848-1856.
37. Gu F, Ma Y, Zhang Z, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010;23:671-676.
38. Huang S, Chen M, Shen Y, et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012;315:198-205.
39. Zalcman G, Bergot E, Creveuil C, Levallet G, Lechapt E. Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. Curr Opin Oncol 2011;23:106-111.
40. Brockstein BE, Vokes EE. Head and neck cancer in 2010: maximizing survival and minimizing toxicity. Nat Rev Clin Oncol 2011;8:72-74.
41. Almasi CE, Brasso K, Iversen P, et al. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate 2011;71:899-907.